Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATRION CORPATRI · Entity 88164 | Director | May 24, 2022 | May 26, 2022 |
| AVANOS MEDICAL, INC.AVNS · Entity 28189 | Director | January 03, 2022 | January 05, 2022 |
| ClearPoint Neuro, Inc.MRIC · Entity 2367 | Director | March 30, 2018 | April 02, 2018 |
| Hyperfine, Inc.HYPR · Entity 6865 | Director · President and CEO | March 31, 2026 | April 01, 2026 |
| IRIDEX CORPIRIX · Entity 7882 | Director | July 23, 2019 | July 25, 2019 |
| Orthofix Medical Inc.OFIX · Entity 1975 | Director | June 08, 2020 | June 10, 2020 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director | June 11, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATRION CORP
Report date May 24, 2022 · Filed May 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284 |
Reported balance
After 2022-05-24 transaction · row 1
1 source rowRow 1 · 2022-05-24 · Grant · Acquired 172 · Balance 284 F1: The Issuer's director compensation policy provides for a grant to the Reporting Person of an award of common stock in an amount equal to $108,000. On May 24, 2022 the Compensation Committee granted an award to each independent director in an annual amount equal to $108,000. F2: The number of shares of common stock granted for all of the awards described above was based on the closing price per share of the Issuer's common stock on May 24, 2022, or $624.50 |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer's director compensation policy provides for a grant to the Reporting Person of an award of common stock in an amount equal to $108,000. On May 24, 2022 the Compensation Committee granted an award to each independent director in an annual amount equal to $108,000.
F2: The number of shares of common stock granted for all of the awards described above was based on the closing price per share of the Issuer's common stock on May 24, 2022, or $624.50
AVANOS MEDICAL, INC.
Report date January 03, 2022 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,396 |
Reported balance
After 2022-01-03 transaction · row 1
1 source rowRow 1 · 2022-01-03 · Grant · Acquired 5,354 · Balance 33,396 F1: Represents restricted share units issued to the reporting person on January 3, 2022 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units issued to the reporting person on January 3, 2022 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan.
ClearPoint Neuro, Inc.
Report date March 30, 2018 · Filed April 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 918 |
Reported balance
After 2018-03-30 transaction · row 1
1 source rowRow 1 · 2018-03-30 · Grant · Acquired 918 · Balance 918 F1: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.13 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2018. |
| Common StockSEC Table I · non-derivative | IndirectMaria Sainz Trust | 919 |
Reported balance
Holding disclosure · report date 2018-03-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 919 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.13 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2018.
Hyperfine, Inc.
Report date March 31, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 789,586 |
Reported balance
After 2026-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 750,000 · Balance 789,586 F1: Consist of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Class A common stock upon vesting. The RSUs vest 25% on March 23, 2027, with the remainder vesting in equal quarterly installments over the following three years, subject to Ms. Sainz's continued service through the applicable vesting date. F2: Consists of 750,000 RSUs granted on March 31, 2026 plus 19,586 shares received on vesting of an RSU award granted on December 23, 2021 and an aggregate of 20,000 purchased shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Consist of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Class A common stock upon vesting. The RSUs vest 25% on March 23, 2027, with the remainder vesting in equal quarterly installments over the following three years, subject to Ms. Sainz's continued service through the applicable vesting date.
F2: Consists of 750,000 RSUs granted on March 31, 2026 plus 19,586 shares received on vesting of an RSU award granted on December 23, 2021 and an aggregate of 20,000 purchased shares.
IRIDEX CORP
Report date July 23, 2019 · Filed July 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,894 |
Reported balance
After 2019-07-23 transaction · row 1
1 source rowRow 1 · 2019-07-23 · Grant · Acquired 11,204 · Balance 16,894 F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of July 23, 2020 or the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of July 23, 2020 or the date of the Issuer's next annual meeting of stockholders.
Orthofix Medical Inc.
Report date June 08, 2020 · Filed June 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,871 |
Reported balance
After 2020-06-08 transaction · row 1
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 4,588 · Balance 40,871 F1: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 3,793 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 3,793 · Balance 3,793 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SPECTRANETICS CORP
Report date August 09, 2017 · Filed August 11, 2017
Section 16 reporting ended · disclosed 2017-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SPNC Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-09 transaction · row 1
1 source rowRow 1 · 2017-08-09 · Disposition to issuer · Disposed 34,276 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes. F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes.
F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 5,328 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 16, 2026 00:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 3,793 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001437749-26-020713 · rdgdoc.xml · derivative · entry 2 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,793 Underlying: Common Stock · 3,793 shares Expires 2036-06-11 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 00:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001437749-26-020713 · rdgdoc.xml · derivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 20:56 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantClass A Common Stock | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-138139 · ownership.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 789,586 F1 · shares: Consist of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Class A common stock upon vesting. The RSUs vest 25% on March 23, 2027, with the remainder vesting in equal quarterly installments over the following three years, subject to Ms. Sainz's continued service through the applicable vesting date. F2 · balance_after: Consists of 750,000 RSUs granted on March 31, 2026 plus 19,586 shares received on vesting of an RSU award granted on December 23, 2021 and an aggregate of 20,000 purchased shares. Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 02:21 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 3,104 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001437749-26-003395 · rdgdoc.xml · derivative · entry 2 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,104 Underlying: Common Stock · 3,104 shares Expires 2036-02-05 F2 · derivative.exercise_date: The shares subject to the option will vest in equal installments on March 5, 2026 and June 5, 2026, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| January 08, 2026 Filed Feb 7, 2026 02:21 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $14.72 | $0.00 |
DisclosureSEC source: 0001437749-26-003395 · rdgdoc.xml · derivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: One-third of the shares subject to the option will vest on the one-year anniversary of the grant and the remaining shares will vest on a monthly basis over two years thereafter, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:38 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerCommon Stock | 5,328 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001642545-24-000118 · wk-form4_1717187671.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2 · price: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Read SEC document |
| March 28, 2024 Filed Mar 28, 2024 22:28 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 1,435,000 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001209191-24-005126 · doc4.xml · derivative · entry 1 Sainz Maria · CIK 0001437768 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,435,000 Underlying: Class A Common Stock · 1,435,000 shares Expires 2034-03-28 F1 · price: The shares underlying this option vest as to 25% on March 28, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to Ms. Sainz's continued service through the applicable vesting date. F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on March 28, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to Ms. Sainz's continued service through the applicable vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:53 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 736 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037559 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,328 Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:24 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 724 | $193.00 | $139,732.00 |
DisclosureSEC source: 0001209191-23-012988 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,592 F1 · price: All reported securities were sold at a price of $193.00. Read SEC document |
| December 14, 2022 Filed Dec 14, 2022 21:59 UTC | Hyperfine, Inc. HYPR · Entity 6865 | PurchaseClass A Common Stock | 5,000 | $0.95 | $4,750.00 |
DisclosureSEC source: 0001209191-22-061247 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,425 Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 23:56 UTC Amendment | Hyperfine, Inc. HYPR · Entity 6865 | PurchaseClass A Common Stock | 12,425 | $0.85 | $10,561.25 |
DisclosureSEC source: 0001209191-22-060775 · doc4a.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,425 Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 21:05 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantClass A Common Stock | 12,425 | $0.85 | $10,561.25 |
DisclosureSEC source: 0001209191-22-060673 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,425 Read SEC document |
| December 08, 2022 Filed Dec 8, 2022 22:54 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantClass A Common Stock | 2,575 | $0.83 | $2,137.25 |
DisclosureSEC source: 0001209191-22-060389 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,161 Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:56 UTC Amendment | Hyperfine, Inc. HYPR · Entity 6865 | PurchaseClass A Common Stock | 2,575 | $0.83 | $2,137.25 |
DisclosureSEC source: 0001209191-22-060774 · doc4a.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,161 Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 21:51 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 3,175,000 | Not disclosed Strike: $0.91 | Not disclosed |
DisclosureSEC source: 0001209191-22-055102 · doc4.xml · derivative · entry 1 Sainz Maria · CIK 0001437768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,175,000 Underlying: Class A Common Stock · 3,175,000 shares Expires 2032-10-24 F1 · price: The shares underlying this option vest as to 25% on October 24, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Ms. Sainz's continued service through the applicable vesting date. F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on October 24, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Ms. Sainz's continued service through the applicable vesting date. Read SEC document |
| September 08, 2022 Filed Sep 10, 2022 00:05 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 650 | $295.00 | $191,750.00 |
DisclosureSEC source: 0001209191-22-049366 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,316 F1 · price: All reported securities were sold at a price of $295.00. Read SEC document |
| June 23, 2022 Filed Jun 28, 2022 00:01 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039544 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,966 Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:10 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Options (right to buy) · Derivative | 85,345 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-22-036280 · doc4.xml · derivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,345 Underlying: Class A Common Stock · 85,345 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Ms. Sainz's continued service through the applicable vesting date. Read SEC document |
| May 24, 2022 Filed May 26, 2022 12:32 UTC | ATRION CORP ATRI · Entity 88164 | GrantCommon Stock | 172 | $0.00 | $0.00 |
DisclosureSEC source: 0001437768-22-000004 · primary_doc.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284 F1 · shares: The Issuer's director compensation policy provides for a grant to the Reporting Person of an award of common stock in an amount equal to $108,000. On May 24, 2022 the Compensation Committee granted an award to each independent director in an annual amount equal to $108,000. F2 · shares: The number of shares of common stock granted for all of the awards described above was based on the closing price per share of the Issuer's common stock on May 24, 2022, or $624.50 Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 16:27 UTC | ATRION CORP ATRI · Entity 88164 | GrantCommon Stock | 18 | $704.90 | $12,688.20 |
DisclosureSEC source: 0001437768-22-000001 · primary_doc.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112 F1 · shares: (1)Acquisition of shares at fair market value in lieu of certain cash fees pursuant to the Atrion Corporation Non-Employee Director Stock Purchase Plan. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 14:53 UTC | AVANOS MEDICAL, INC. AVNS · Entity 28189 | GrantCommon Stock | 5,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001606498-22-000013 · wf-form4_164139441567536.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,396 F1 · shares: Represents restricted share units issued to the reporting person on January 3, 2022 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document |
| December 23, 2021 Filed Dec 24, 2021 02:41 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantClass A Common Stock | 16,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-153331 · tm2135698-14_4seq1.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,483 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Ms. Sainz's continued service through the applicable vesting date. Read SEC document |
| December 23, 2021 Filed Jan 11, 2022 02:37 UTC Amendment | Hyperfine, Inc. HYPR · Entity 6865 | GrantClass A Common Stock | 19,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-002886 · tm222483-1_4aseq1.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,586 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Ms. Sainz's continued service through the applicable vesting date. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 14:29 UTC | ATRION CORP ATRI · Entity 88164 | GrantCommon Stock | 94 | $703.63 | $66,141.22 |
DisclosureSEC source: 0001437768-21-000001 · primary_doc.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94 F1 · shares: The Issuer's director compensation policy provides for a grant to the Reporting Person of an annual award of common stock in an amount equal to $92,000. On August 30, 2021, the Compensation Committee granted an award to Ms. Maria Sainz in an amount equal to $66,290 which is the pro rated portion of the annual amount for the remaining portion of the year until the Annual Stockholders meeting. F2 · shares: The number of shares of common stock issued for the award described above was based on the closing price per share of the Issuer's common stock on August 30, 2021, or $703.63. Read SEC document |
| June 28, 2021 Filed Jul 10, 2021 01:41 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 850 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-010317 · dp154195_4-sainz.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,972 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The shares subject to the restricted stock units vest on 6/25/2022, subject to the Reporting Person's continued service through such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 15:18 UTC | AVANOS MEDICAL, INC. AVNS · Entity 28189 | GrantCommon Stock | 4,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001606498-21-000002 · wf-form4_160994629216829.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,042 F1 · shares: Represents restricted share units issued to the reporting person on January 4, 2021 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 20:50 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 4,122 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-013899 · dp132549_4-sainz.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,122 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the issuer's common stock. The shares subject to the restricted stock units vest in equal annual installments over three years commencing on July 16, 2020, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:59 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 4,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035655 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,871 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020. Read SEC document |
| January 02, 2020 Filed Jan 8, 2020 21:19 UTC | AVANOS MEDICAL, INC. AVNS · Entity 28189 | GrantCommon Stock | 5,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001606498-20-000006 · wf-form4_157851837459823.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,037 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2020 pursuant to the Avanos Medical, Inc. Outside Director's Compensation Plan. Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 23:08 UTC | IRIDEX CORP IRIX · Entity 7882 | GrantCommon Stock | 11,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043280 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,894 F1 · shares: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of July 23, 2020 or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 22:02 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 3,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036918 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,833 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 11, 2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 14:46 UTC | AVANOS MEDICAL, INC. AVNS · Entity 28189 | GrantCommon Stock | 4,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001606498-19-000008 · wf-form4_154661317000482.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,744 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2019, pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document |
| July 17, 2018 Filed Jul 17, 2018 23:02 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-042922 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,167 F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019. Read SEC document |
| June 13, 2018 Filed Jun 16, 2018 00:10 UTC | IRIDEX CORP IRIX · Entity 7882 | GrantCommon Stock | 5,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001704739-18-000028 · edgar.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,690 F1 · shares: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of June 13, 2019 or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 03, 2018 Filed May 4, 2018 14:38 UTC | AVANOS MEDICAL, INC. HYH · Entity 28189 | GrantCommon Stock | 384 | $0.00 | $0.00 |
DisclosureSEC source: 0001606498-18-000041 · wf-form4_152544466951497.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,496 F1 · shares: Represents restricted share units issued to the reporting person on May 3, 2018 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 21:45 UTC | IRIDEX CORP IRIX · Entity 7882 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.69 | $0.00 |
DisclosureSEC source: 0001704739-18-000009 · edgar.xml · derivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-04-13 F1 · security: The option was granted pursuant to IRIDEX Corporation's 2008 Amended and Restated Equity Incentive Plan and is exempt pursuant to Rule 16b-3. F2 · derivative.exercise_date: The shares are subject to vesting according to the following schedule: 1/48th of the total number of shares vest on May 13, 2018 and each month thereafter. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 20:58 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 918 | $3.13 | $2,873.34 |
DisclosureSEC source: 0001534424-18-000114 · sainz.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.13 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2018. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 22:14 UTC | AVANOS MEDICAL, INC. HYH · Entity 28189 | GrantCommon Stock | 2,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001606498-18-000011 · wf-form4_151501767901653.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,112 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2018 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:24 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001534424-17-000502 · sainz.xml · derivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2018 annual meeting of stockholders. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 14:33 UTC | SPECTRANETICS CORP SPNC · Entity 173862 | Disposition to issuerSPNC Common Stock | 34,276 | $38.50 | $1,319,626.00 |
DisclosureSEC source: 0001179110-17-011356 · edgar.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes. F2 · shares: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest. Read SEC document |
| July 03, 2017 Filed Jul 10, 2017 21:58 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 3,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044653 · doc4.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,812 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 3, 2018. Vested shares of common stock will be delivered to the reporting person within 45 days after termination of service as a director. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 17:25 UTC | SPECTRANETICS CORP SPNC · Entity 173862 | GrantSPNC Common Stock | 4,780 | $0.00 | $0.00 |
DisclosureSEC source: 0000789132-17-000096 · wf-form4_149730271773746.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,276 F1 · shares: Director compensation grant of SPNC restricted stock, vesting over 1 year, 100% vested on 6/8/2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 14:27 UTC | AVANOS MEDICAL, INC. HYH · Entity 28189 | GrantCommon Stock | 3,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001606036-17-000002 · primary_doc.xml · nonDerivative · entry 1 Sainz Maria · CIK 0001437768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,166 F1 · shares: Represents restricted share units issued to the reporting person on January 3, 2017 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.